<DOC>
	<DOCNO>NCT02184299</DOCNO>
	<brief_summary>Study determine incidence rash group receive nevirapine without prednisone group receive nevirapine prednisone</brief_summary>
	<brief_title>Study Nevirapine Prednisone Determine Safety Effectiveness Preventing Nevirapine Associated Rash Human Immunodeficiency Virus ( HIV ) Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Male female patient ethnic group age 18 65 year age Women childbearing potential utilize adequate birth control prevent pregnancy study duration . Due possibility study drug could alter effectiveness oral contraceptive depoprogesterone , oral contraceptive depoprogesterone use sole form birth control duration study Women childbearing potential negative serum human chorionic gonadotropin ( bhCG ) within 14 day prior initiation study therapy Presence HIV1 infection document licensed EnzymeLinked Immunosorbent Assay ( ELISA ) test kit confirm either Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA time prior study entry A CD4+ cell count 100 cells/mm³ document within 30 day baseline visit . If patient history clinical AIDS defining event , i.e . Pneumocystis carinii pneumonia ( PCP ) , Kaposi sarcoma , etc , his/her CD4+ cell count &gt; = 200 cells/mm³ Patients could either ) prior antiretroviral therapy b ) prior antiretroviral therapy NonNucleoside Reverse Transcriptase Inhibitors ( NNRTI ) therapy . Antiretroviral experience patient eligible enroll study patient follow characteristic Switching Patients : Patients two consecutive ultrasensitive HIVRNA assay result limit quantification ( BLQ ) least one week apart Patients Optimizing Therapy : Patients respond substantial drop HIVRNA count without reach BLQ patient fail current regimen need change new drug regimen Patients Restarting Therapy : Patients antiretroviral experience received antiretroviral therapy previous three month enrol study All antiretroviral experienced patient stable regimen least three month immediately prior enrollment antiretroviral therapy least three month immediately prior enrollment Ability willingness give write informed consent comply study requirement Patients must ambulatory performance score &gt; = 80 Karnofsky scale Female patient pregnant breastfeed Patients acute and/or active AIDS defining illness History illness drug allergy opinion Investigator could confound result study pose additional risk administer nevirapine patient Patients active invasive infection include pneumonia , septicemia , meningitis encephalitis ; include upper respiratory infection , dermatologic infection , oral infection urinary tract infection Patients currently take prescription nonprescription drug opinion investigator consultation Boehringer Ingelheim Pharmaceuticals Incorporated ( BIPI ) medical monitor could interfere either absorption , distribution metabolism nevirapine prednisone The following laboratory parameter document within 30 day prior baseline visit : Hemoglobin &lt; 9.1 g/dL men ; &lt; 8.9 g/dL woman Absolute neutrophil count &lt; 750 cells/mm³ Platelet count &lt; 50000 platelets/mm³ AST ( SGOT ) /ALT ( SGPT ) &gt; five time upper limit normal range ( ULN ) Creatinine &gt; two time ULN Documented suspect acute hepatitis within 30 day prior baseline visit irrespective Aspartate Aminotransferase ( AST ) Serum GlutamicOxaloacetic Transaminase ( SGOT ) Alanine Aminotransferase ( ALT ) Serum GlutamicPyruvic Transaminase ( SGPT ) value five time ULN Unexplained temperature &gt; 38.5 °C seven day chronic diarrhea define three stool per day persist 15 day within 30 day prior baseline visit History illness contraindicate use prednisone hypertension , diabetes disease adrenopituitary axis . Any chronic gastrointestinal condition could interfere study drug absorption Receipt follow Any NNRTI therapy anytime prior baseline visit Interferons , interleukins vaccine include HIV vaccine within 30 day prior baseline visit Any investigational agent need continue study Abacavir Patients would take known inhibitor inducer P450 metabolic enzyme include ketoconazole , itraconazole , rifampin phenytoin enrol . In addition follow drug allow study : cytochrome P450 3A4 substrate terfenadine , astemizole , cisapride , triazolam midazolam . Nonnucleoside reverse transcriptase inhibitor studyprovided nevirapine allow The presence skin rash mucosal lesion opinion Investigator could compromise wellbeing patient confound assessment nevirapineassociated rash . Localized skin rash ( e.g . facial folliculitis contact dermatitis ) basis exclusion trial Presence occult ( microscopic ) frank ( macroscopic ) blood stool Any medical condition opinion Investigators would interfere patient 's ability participate adhere requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>